Anixa Biosciences Inc ANIX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-42.76
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$10.9M | — | — | $15.2M |
| 2024 | $210,000 | -$12.6M | — | — | $18.9M |
| 2023 | $210,000 | -$9.8M | — | — | $23.4M |
| 2022 | — | -$13.6M | — | — | $28.2M |
| 2021 | $512,000 | -$13.0M | — | — | $34.8M |
| 2020 | — | -$10.0M | — | -$6.2M | $8.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Titterton Lewis H jr | director | 2026-06-16 | Buy | 2,836 | $2.64 |
| KUMAR AMIT | Chief Executive Officer | 2026-06-12 | Buy | 21,000 | $2.50 |
| Baskies Arnold M | director | 2026-01-28 | Buy | 10,000 | $3.04 |
| Titterton Lewis H jr | director | 2025-12-15 | Option exercise | 16,000 | $2.92 |
| KUMAR AMIT | Chief Executive Officer | 2025-10-30 | Option exercise | 200,000 | $2.92 |
| KUMAR AMIT | Chief Executive Officer | 2025-10-30 | Tax withheld | 169,439 | $4.06 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -42.76 (distress)
- Working capital / assets 0.866
- Retained earnings / assets -15.652
- EBIT / assets -0.728
- Equity / liabilities 7.118
Source: SEC EDGAR filings · CIK 0000715446 · as of 2025-10-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.